

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
MARKET ANALYSES AND FORECASTS	2
METHODOLOGY	2
INTENDED AUDIENCE.....	3
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED REPORTS	3
BCC ONLINE SERVICES.....	4
DISCLAIMER	4
CHAPTER TWO: SUMMARY.....	5
SUMMARY.....	5
MARKET SIZE AND EVOLUTION.....	6
<i>SUMMARY TABLE MAJOR GENERICS MARKETS, THROUGH 2016 (\$</i>	
<i>BILLIONS)</i>	7
<i>SUMMARY FIGURE MAJOR GENERICS MARKETS, THROUGH 2016</i>	
<i>(\$ BILLIONS)</i>	7
CHAPTER THREE: OVERVIEW	8
OVERVIEW.....	8
OVERVIEW (CONTINUED)	9
<i>TABLE 1 GLOBAL PHARMACEUTICAL AND GENERICS MARKETS,</i>	
<i>THROUGH 2016 (\$ BILLIONS)</i>	10
RECENT HISTORY OF THE GENERICS SECTOR.....	11
ROCHE-BOLAR	11
Roche-Bolar (Continued)	12
GENERICS LOBBY	13
ICH.....	14
CHAPTER FOUR: THE NEW GENERICS ERA.....	15
THE PATENT CLIFF	16
<i>TABLE 2 FIRST PATENT EXPIRIES, 2012–2023</i>	17
TYPES OF GENERICS	17
“SIMPLE” GENERICS.....	17
Factors Influencing the Success or Failure of Generics.....	18
Adequate Market Size	18
Patent-Expired Therapies	18
Older Products Still Used.....	19
Long-Term Use	19
Straightforward Production Technology.....	19
Drugs Used in Primary Care.....	20

SUPERGENERICS	20
BIOSIMILARS.....	21
Biosimilars (Continued)	22
<i>TABLE 3 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS,</i>	
<i>2001–2006.....</i>	<i>23</i>
Special Challenges.....	24
Special Challenges (Continued)	25
The Biosimilar Market	26
Some Biosimilar Developments and Introductions.....	26
EPO	26
G-CSF.....	26
Interferons.....	26
HGH	27
Monoclonal Antibodies.....	27
Monoclonal ... (Continued).....	28
MAJOR GENERIC ISSUES.....	29
REGULATORY ENVIRONMENT.....	29
U.S.....	29
<i>TABLE 4 REQUIREMENTS FOR NDA AND ANDA APPLICATIONS.....</i>	<i>30</i>
U.S. (Continued)	31
European Union.....	32
EU Marketing Authorization Systems	32
• The Centralized Procedure.....	33
• Decentralized and Mutual Recognition	
Procedures.....	34
• Mutual-Recognition Procedure	34
Types of Applications.....	35
• Applications Under Article 10 (Generic	
Products)	35
Japan.....	36
Approval (Shonin) of Pharmaceuticals	37
REGULATION OF BIOSIMILARS	37
EU Provisions	38
Evolving Situation in the U.S.	39
Hatch-Waxman and Bolar.....	39
Defensive Strategies by “Big Pharma”	40
“AUTHORIZED GENERICS”	41
User Fees	42
A “Mood Swing” Toward Generics	43
The Situation in Europe	44
PATENTS AND IP.....	45
SUPPLEMENTARY PROTECTION CERTIFICATES	46
Supplementary Protection Certificates (Continued).....	47

CHAPTER FIVE: THE GLOBAL PHARMACEUTICAL AND GENERICS MARKET	48
GLOBAL GENERICS MARKET	48
MAIN NATIONAL GENERICS MARKETS	49
TABLE 5 WORLD PHARMA AND GENERICS MARKETS, THROUGH 2016 (\$ BILLIONS).....	49
TABLE 6 CURRENT AND FORECAST NATIONAL GENERICS MARKETS, THROUGH 2016 (\$ BILLIONS).....	50
MARKET OPPORTUNITIES BY PRODUCT CLASS	50
LEADING GENERIC MOLECULES	50
TABLE 7 WIDELY PRESCRIBED GENERIC MOLECULES IN THE U.S. AND EUROPE	50
TABLE 7 (CONTINUED).....	51
Anti-infectives.....	51
Anti-infectives (Continued)	52
TABLE 8 LEADING ANTI-INFECTIVE PRODUCTS SALES ESTIMATES WITH YEAR OF PATENT EXPIRY, 2010 (\$ BILLIONS).....	53
CNS Therapies.....	54
TABLE 9 CNS MARKET BY MAJOR INDICATIONS, 2010 (\$ BILLIONS).....	54
FIGURE 1 CNS MARKET SHARES BY MAJOR INDICATIONS, 2010 (%).....	55
Antidepressants	55
Antipsychotics	56
TABLE 10 LEADING CNS PRODUCT SALES ESTIMATES, 2010 (\$ BILLIONS).....	57
Anxiolytics.....	57
Sleep Disorders	58
Epilepsy.....	58
Parkinson's Disease.....	59
Migraine.....	59
Cardiovascular Products	60
TABLE 11 LEADING CARDIOVASCULAR PRODUCT SALES, 2009 (\$ BILLIONS).....	61
Anti-arthritis Products	62
Steroids.....	62
NSAIDs.....	63
COX- II Inhibitors.....	63
DMARDs	64
TABLE 12 LEADING ANTI-ARTHRITIS PRODUCT SALES ESTIMATES, 2009 (\$ BILLIONS).....	65
Respiratory Products	66
Asthma	66
COPD.....	66

Allergic Rhinitis	67
Allergic ... (Continued)	68
<i>TABLE 13 LEADING RESPIRATORY PRODUCT SALES ESTIMATES,</i>	
<i>2009 (\$ BILLIONS)</i>	69
• Drugs Used to Treat Asthma and COPD	69
– Bronchodilators	69
– Inhaled Bronchodilators	69
– Anticholinergics.....	70
– Oral Bronchodilators	70
– Leukotriene Antagonists	70
– Steroids	71
<i>FIGURE 2 USAGE OF MAIN PRODUCT CATEGORIES BASED</i>	
<i>REVENUES (%)</i>	71
<i>FIGURE 2 (CONTINUED)</i>	72
Anticancer Products	72
Cytotoxic Drugs.....	72
Hormonal Therapy	72
Biologic Response Modifiers	73
Antiangiogenesis Drugs.....	73
Monoclonal Antibodies.....	73
<i>TABLE 14 LEADING ANTICANCER PRODUCT SALES ESTIMATES,</i>	
<i>2009 (\$ BILLIONS)</i>	74
Monoclonal Antibodies (Continued)	75
 CHAPTER SIX: THE AMERICAN MARKET	76
THE U.S. MARKET	76
VITAL STATISTICS	76
HEALTH AND HEALTHCARE	76
Health and Healthcare (Continued)	77
THE U.S. PHARMACEUTICAL MARKET	78
THE GENERICS MARKET: SIZE AND GROWTH	78
Biosimilars	79
Generic Prices	79
“Carve-Outs”	80
Generics Industry	80
<i>FIGURE 3 U.S. PHARMACEUTICAL MARKET SHARES BASED ON</i>	
<i>DOLLAR SALES AND PERCENTAGE SHARE OF PRESCRIPTIONS</i>	
<i>BY TYPE, 2010 (%)</i>	81
<i>FIGURE 3 (CONTINUED)</i>	82
The Future	83
<i>TABLE 15 U.S. PHARMACEUTICAL AND GENERICS MARKETS,</i>	
<i>THROUGH 2016 (\$ BILLIONS)</i>	84
CANADA	84
VITAL STATISTICS	84
HEALTH AND HEALTHCARE	85

THE PHARMACEUTICAL MARKET.....	86
GENERICIS	86
Generic Prices	87
Future Market Growth.....	88
How Generics are Supplied	88
<i>TABLE 16 GENERICS MARKET IN CANADA, THROUGH 2016 (\$</i>	
<i>BILLIONS)</i>	89
LATIN AMERICA.....	89
BRAZIL.....	90
Vital Statistics	90
Health and Healthcare.....	90
Pharmaceutical Market.....	91
Generics Market	92
M&A Activity	92
Background	93
Background (Continued)	94
PróGenéricos	95
<i>TABLE 17 PHARMACEUTICAL AND GENERICS MARKET IN BRAZIL,</i>	
<i>THROUGH 2016 (\$ BILLIONS)</i>	95
MEXICO	95
Vital Statistics	95
Health and Healthcare.....	96
Pharmaceutical Market.....	96
Market Resisters.....	97
Generic Sector.....	97
Generic Industry	98
Regulatory Issues.....	99
AMEGI	100
Forecasts	100
<i>TABLE 18 PHARMACEUTICAL AND GENERICS MARKET IN</i>	
<i>MEXICO, THROUGH 2016 (\$ BILLIONS)</i>	101
CHAPTER SEVEN: THE EUROPEAN MARKET.....	102
<i>TABLE 19 PHARMACEUTICAL PRICES IN EUROPE AND U.S., 2000-</i>	
<i>2008 (\$)</i>	102
FRANCE.....	103
VITAL STATISTICS	103
HEALTH AND HEALTHCARE	104
Healthcare Provision	104
<i>FIGURE 4 TOTAL EXPENDITURES ON HEALTH IN MAJOR</i>	
<i>EUROPEAN MARKETS AND THE U.S. AS A PERCENTAGE OF</i>	
<i>GDP, 2007 (%)</i>	105
PHARMACEUTICAL MARKET	106
GENERIC SECTOR.....	106

<i>TABLE 20 PHARMACEUTICAL AND GENERICS MARKET IN FRANCE, THROUGH 2016 (\$ BILLIONS)</i>	107
GERMANY	108
VITAL STATISTICS	108
HEALTH AND HEALTHCARE	108
Provision of Healthcare	108
PHARMACEUTICAL MARKET	109
Price Controls	109
GENERICS SECTOR.....	110
<i>TABLE 21 PHARMACEUTICAL AND GENERICS MARKET IN GERMANY, THROUGH 2016 (\$ BILLIONS)</i>	111
ITALY	111
VITAL STATISTICS	111
HEALTH AND HEALTHCARE	112
Healthcare System	112
PHARMACEUTICAL MARKET	113
Implications for Research.....	114
<i>TABLE 22 SELECTED PRIORITY AREAS IN ITALY'S NATIONAL HEALTH PLAN</i>	115
GENERICS SECTOR.....	115
Generics Sector (Continued)	116
<i>TABLE 23 PHARMACEUTICAL AND GENERICS MARKET IN ITALY, THROUGH 2016 (\$ BILLIONS)</i>	117
SPAIN.....	117
VITAL STATISTICS	117
HEALTH AND HEALTHCARE	117
Healthcare Provision	118
Pharmaceutical Services	119
PHARMACEUTICAL MARKET	119
GENERICS SECTOR.....	120
Generics Industry	121
<i>TABLE 24 LEADING GENERICS COMPANIES IN SPAIN, 2010 (\$ MILLIONS)</i>	121
<i>TABLE 25 PHARMACEUTICAL AND GENERICS MARKET IN SPAIN, THROUGH 2016 (\$ BILLIONS)</i>	122
UNITED KINGDOM.....	122
VITAL STATISTICS	122
HEALTH AND HEALTHCARE	122
Healthcare Provision	123
Private Sector Involvement.....	123
Pharmaceuticals.....	124
THE PHARMACEUTICAL MARKET.....	124
GENERICS SECTOR.....	125

<i>TABLE 26 PHARMACEUTICAL AND GENERICS MARKET IN THE UNITED KINGDOM, THROUGH 2016 (\$ BILLIONS)</i>	126
RUSSIA	126
VITAL STATISTICS	126
HEALTH AND HEALTHCARE	127
Healthcare Delivery.....	127
PHARMACEUTICAL MARKET	127
“Pharma 2020”	128
GENERICS SECTOR.....	128
<i>TABLE 27 PHARMACEUTICAL AND GENERICS MARKET IN RUSSIA, THROUGH 2016 (\$ BILLIONS)</i>	129
CHAPTER EIGHT: THE ASIAN REGION	130
JAPAN.....	130
VITAL STATISTICS	130
HEALTH AND HEALTHCARE	130
PHARMACEUTICAL MARKET	131
<i>TABLE 28 TOP 5 JAPANESE PHARMA COMPANIES, 2008 (%)</i>	132
GENERICS SECTOR.....	133
Foreign Presence	134
Market Resistance	135
Generics Industry	136
<i>TABLE 29 JAPANESE PHARMACEUTICAL AND GENERICS MARKET, 2011–2016 (\$ BILLIONS)</i>	137
INDIA	137
VITAL STATISTICS	137
HEALTH AND HEALTHCARE	137
Growing Affluence—Changing Medical Needs	138
Regulatory Changes	138
PHARMACEUTICAL MARKET	138
Demographic Factors.....	139
Pharma Industry	139
Patent Reform.....	140
GENERICS INDUSTRY	141
<i>TABLE 30 LEADING PHARMA COMPANIES IN INDIA, 2010 (\$ MILLIONS)</i>	141
<i>TABLE 31 PHARMACEUTICAL AND GENERICS MARKET IN INDIA, THROUGH 2016 (\$ BILLIONS)</i>	142
CHINA.....	142
VITAL STATISTICS	142
HEALTH AND HEALTHCARE	142
Health and Healthcare (Continued)	143
PHARMACEUTICAL MARKET	144
Domestic Industry	145
Foreign Company Involvement.....	146

Importance of R&D.....	147
Challenges.....	148
Market Trends	148
Regulatory Changes	149
Generic Exports	149
Domestic Generics Market.....	150
Local Dominance.....	151

FIGURE 5 GENERICS MARKET THERAPEUTIC CATEGORIES 2008

(%).....	152
----------	-----

TABLE 32 PHARMACEUTICAL AND GENERICS MARKET, CHINA,

THROUGH 2016 (\$ BILLIONS).....	153
--	------------

CHAPTER NINE: PROFILES OF THE TOP TEN GENERICS COMPANIES ... 154

TABLE 33 LEADING GENERICS MANUFACTURERS, 2010 (\$

BILLIONS/%).....	154
-------------------------	------------

TRENDS.....	154
-------------	-----

STRUCTURE OF THE GENERICS INDUSTRY.....	155
---	-----

PROFILES OF TOP 10 GENERICS COMPANIES	156
---	-----

ACTAVIS	156
---------------	-----

Actavis (Continued)	157
---------------------------	-----

APOTEX INC.....	158
-----------------	-----

DR. REDDY'S LABORATORIES, LTD.	159
-------------------------------------	-----

Acquisitions.....	160
-------------------	-----

Financials.....	161
-----------------	-----

HOSPIRA, INC.....	161
-------------------	-----

Biogenerics.....	162
------------------	-----

Financials.....	163
-----------------	-----

MYLAN INC.	163
-----------------	-----

Mylan Inc. (Continued).....	164
-----------------------------	-----

Financials.....	165
-----------------	-----

Looking Ahead	165
---------------------	-----

PAR PHARMACEUTICAL, INC.	165
-------------------------------	-----

Generics	166
----------------	-----

Financials.....	166
-----------------	-----

RANBAXY LABORATORIES, LTD.	167
---------------------------------	-----

History.....	167
--------------	-----

Acquisition by Daiichi Sankyo	168
-------------------------------------	-----

Financials.....	169
-----------------	-----

Looking Ahead	169
---------------------	-----

SANDOZ INTERNATIONAL GMBH.....	170
--------------------------------	-----

Products	170
----------------	-----

TEVA PHARMACEUTICAL INDUSTRIES, LTD.....	171
--	-----

Teva Pharmaceutical Industries, Ltd. (Continued)	172
--	-----

Financials.....	173
-----------------	-----

WATSON PHARMACEUTICALS, INC.	174
-----------------------------------	-----

Products	174
Financials.....	174
Looking Ahead	175

CHAPTER TEN: PROFILES OF OTHER INTERNATIONAL GENERICS

COMPANIES.....	176
PROFILES.....	176
ALAPIS GROUP.....	176
AMNEAL PHARMACEUTICALS, LLC.....	177
Amneal Pharmaceuticals Co. India Pvt., Ltd.....	177
ASPEN PHARMACARE HOLDINGS, LTD.	178
Financial Results.....	179
AUROBINDO PHARMA, LTD.	180
Products	180
Financials.....	181
Looking Ahead	181
BERLIN-CHEMIE AG	181
BIOCON.....	182
Biocon U.S.....	182
Biocon U.S. (Continued)	183
Biocon U.S. (Continued)	184
BIOGARAN FRANCE.....	185
CIPLA, LTD.....	186
COBALT	187
EGIS PHARMACEUTICALS, PLC	188
APIs.....	189
Pharmaceutical R&D.....	189
GEDEON RICHTER, PLC.....	190
GENEPHARM GROUP.....	191
KRKA, D.D., NOVO MESTO	192
Products	193
Financials.....	194
Looking Ahead	194
KV PHARMACEUTICAL CO.	194
LUPIN, LTD.	194
Lupin, Ltd. (Continued).....	195
MITSUBISHI TANABE PHARMA CORP.	196
Tanabe Seiyaku Hanbai Co., Ltd.....	196
NICHI-IKO PHARMACEUTICAL CO., LTD.	197
Products	197
Financials.....	198
Looking Ahead	198
NIPPON CHEMIPHAR CO., LTD.....	198
Financials.....	199
Looking Ahead	199

NOVARTIS INTERNATIONAL AG	199
Looking Ahead	200
ORION CORP.	200
Products	200
Generics	201
Financials.....	201
Looking Ahead	201
PFIZER INC.	201
U.S. Basic Patent Expiry.....	202
<i>TABLE 34 PFIZER'S U.S. PATENT EXPIRIES, THROUGH 2021</i>	<i>202</i>
Financials.....	203
PLIVA D.D.	203
ROXANE LABORATORIES, INC.	204
SANOFI-AVENTIS	205
Looking Ahead	206
SAWAI PHARMACEUTICAL	206
Products	207
Financials.....	207
Looking Ahead	207
STADA ARZNEIMITTEL	208
Generics	208
Biosimilars	209
Financials.....	209
Looking Ahead	209
STRIDES ARCOLAB, LTD.	210
Product Range.....	211
Looking Ahead	211
WOCKHARDT, LTD.	212
Financials.....	213
Looking Ahead	213
ZYDUS CADILA.....	214
Zydus U.S. Corporate Office.....	214
Zydus U.S. ... (Continued).....	215